Key facts
- Sarvas Health’s last known valuation is $1.1M (Sep 2025).
- It has raised $80K; the latest was Early Stage VC ($80K) in Sep 2025.
- Notable investors include UK Research and Innovation, Bethnal Green Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Sarvas Health
- ·The full record, as it builds
Funding rounds
No funding rounds for Sarvas Health are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sarvas Health
Developer of an AI-powered diagnostic decision support platform designed to identify chronic health conditions at an early stage. The company offers AI models trained on clinical data, medical record analysis, and disease risk prediction capabilities, enabling healthcare providers and life sciences organizations to identify potential health risks earlier and support timely diagnosis and treatment.
- Sector
- Healthcare
- HQ
- Manchester, United Kingdom
- Founded
- 2024
- Employees
- 2
- Website
- sarvas.co.uk/
- Ownership
- Privately Held (backing)
Sarvas Health doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sarvas Health shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sarvas Health in its N-PORT filings yet. We sweep new filings monthly.